ANGLE (AGL) Share Forecast, Price & News

ANGLE (LON:AGL) Frequently Asked Questions

Is ANGLE a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANGLE in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANGLE stock.
View analyst ratings for ANGLE or view top-rated stocks.

How were ANGLE's earnings last quarter?

ANGLE plc (LON:AGL) released its quarterly earnings data on Thursday, January, 30th. The company reported ($3.33) earnings per share for the quarter.
View ANGLE's earnings history.

What price target have analysts set for AGL?

1 brokerages have issued 1-year price objectives for ANGLE's stock. Their forecasts range from GBX 195 to GBX 195. On average, they expect ANGLE's share price to reach GBX 195 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for ANGLE or view top-rated stocks among Wall Street analysts.

Who are ANGLE's key executives?

ANGLE's management team includes the following people:

• Mr. Andrew David William Newland, Founder, CEO & Exec. Director (Age 60, Pay $392k)
• Mr. Ian Francis Griffiths, CFO, Fin. Director, Company Sec. & Exec. Director (Age 57, Pay $251k)
• Mr. Andrew John Holder, Head of Investor Relations
• Mr. Paul Smith, Chief Commercial Officer
• Dr. Madeline Repollet, Head of Clinical Laboratories
• Ms. Anne-Sophie Pailhes-Jimenez, Head of R&D - ANGLE Europe Ltd.
• Mr. Martin Cooke, Director of Manufacturing & Regulatory Affairs (Age 53)
• Mr. Michael O'Brien, Bus. Devel. Director

Who are some of ANGLE's key competitors?

Some companies that are related to ANGLE include GreenLight Biosciences (GRNA), Recursion Pharmaceuticals (RXRX), BellRing Brands (BRBR), Zentalis Pharmaceuticals (ZNTL), Sana Biotechnology (SANA), Intersect ENT (XENT), LeMaitre Vascular (LMAT), Heska (HSKA), Antares Pharma (ATRS), Hydropothecary (THCX), NGM Biopharmaceuticals (NGM), TG Therapeutics (TGTX), Cerus (CERS), Sharecare (SHCR) and FibroGen (FGEN).
View all of AGL's competitors.

What other stocks do shareholders of ANGLE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANGLE investors own include Yamana Gold (YRI), Asiamet Resources (ARS), Dekel Agri-Vision (DKL), Eldorado Gold (ELD), Polo Resources (POL), Silvercorp Metals (SVM), First Majestic Silver (AG), AFPO.L (AFPO), Ariana Resources (AAU) and Alamos Gold (AGI).

What is ANGLE's stock symbol?

ANGLE trades on the London Stock Exchange (LON) under the ticker symbol "AGL."

How do I buy shares of ANGLE?

Shares of AGL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ANGLE's stock price today?

One share of AGL stock can currently be purchased for approximately GBX 103.48.

How much money does ANGLE make?

ANGLE has a market capitalization of £243.32 million and generates £1.01 million in revenue each year.

How many employees does ANGLE have?

ANGLE employs 102 workers across the globe.

What is ANGLE's official website?

The official website for ANGLE is www.angleplc.com.

How can I contact ANGLE?

ANGLE's mailing address is The Surrey Research Park 3 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-685830.